Concepedia

Author

Alexander Starodub

Goshen Health

Also Known As

A N Starodub, A. N. Starodub, A. Starodub, A.N. Starodub, Alexander N Starodub, Alexander N. Starodub, Alexander Starodub, Bahary, Nathan

208

Publications

3.3K

Citations

24

H-Index

60

Concepts

All Affiliations

Goshen HealthIndiana University HealthSarah CannonCornell UniversityDana-Farber Cancer Institute
AS

About

Alexander Starodub is an author at Goshen Health specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

27

1.2K

2

Health Sciences

6

6

183

3

Engineering

3

3

76

4

Applied Physics

1

1

10

5

Biomedical Engineering

1

1

22

Alexander Starodub

×

48

Publications

3K

Citations

24

H-Index

YearCitations

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond,

Journal of Clinical Oncology

2017

386

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio,

Annals of Oncology

2021

349

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander Starodub, Allyson J. Ocean, Manish A. Shah,

Clinical Cancer Research

2015

341

Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

Allyson J. Ocean, Alexander Starodub, Aditya Bardia,

Cancer

2017

227

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters,

Journal of Clinical Oncology

2017

181

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub,

Clinical Cancer Research

2017

155

Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

Efrat Dotan, Steven J. Cohen, Alexander Starodub,

Journal of Clinical Oncology

2017

115

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes

Matthew D. Galsky, Huan Wang, Noah M. Hahn,

European Urology

2017

113

652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

Kathryn C. Arbour, Salman R. Punekar, Ignacio Garrido‐Laguna,

Annals of Oncology

2023

102

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Manish A. Shah, Alexander Starodub, Sunil Sharma,

Clinical Cancer Research

2018

90

Page 1